FIMM is an independent translational research institute focusing on human genomics and precision medicine, under the umbrella of the Helsinki Institute of Life Science at the University of Helsinki. FIMM has a driving mission to perform innovative research on patients and populations targeted towards understanding drivers of health and disease. We aim to delivering improvements to the safety, efficacy, and efficiency of healthcare in Finland and beyond. FIMM has > 230 employees representing tens of nationalities and a budget of 23 M€, with >85% coming from competitive sources. FIMM is also the Finnish node of the Nordic EMBL Partnership for Molecular Medicine.
FIMM is located on the Meilahti campus, in building Biomedicum 2U. Our street address is Tukholmankatu 8, 00290 Helsinki.
Map below: Please note that, instead of Biomedicum (red), the blue/grey pointer for Institute for Molecular Medicine Finland is to be clicked for correct coordinates.
"Our sense of community makes us strong."
For us at FIMM, a vibrant work atmosphere, positive attitude and strong support within a local community are essential. We understand the importance of wellbeing and work to foster it through approaches such as peer mentoring, soft skills training and group retreats. We value an open and transparent management culture in which all employees are encouraged to voice their opinions. The aim of our regular informal institute meetings is to keep our staff well-informed about future developments and to give everyone a chance to participate in the dialogue. The FIMM Student and Postdoc Council and the FIMMPOD programme have proven to be great ways to support our doctoral students, postdocs, coordinators and senior researches and to build team spirit within this community.
FIMM is the leading genetics and genomics research unit in Finland. We offer an internationally recognized, unique biomedical research environment in Helsinki.
Are you interested in joining us?
More information about the possibilities we offer is available on our career page.
Over 230 researchers, coordinators and laboratory and IT experts work together at FIMM to advance our scientific goals. Most of our staff members work in scientific roles. Our research is delivered by these talented scientists, ranging from research directors and group leaders, through senior researchers, postdoctoral researchers, doctoral students and research assistants. Both our researchers and external customers rely on the support and expertise provided by our research support personnel, many of whom are also Ph.D. level scientists.
Our working environment is both multidisciplinary and international. Our staff members hold expertise in many different scientific disciplines, the majority having a biology, biochemistry, bioinformatics or medical background. They also come from all over the world: In September 2020, a third of our personnel was international, representing 28 different nationalities.
Mark Daly, Director of FIMM
Mark Daly was appointed the FIMM Director with effect from February 1, 2018. He joined FIMM from the Broad Institute of MIT and Harvard and Massachusetts General Hospital. He is a distinguished scientist who has made major contributions to human genetics and genomics during his 20-year career.
To contact Mark Daly, please e-mail to: email@example.com, or contact Susanna Rosas:
Vice Director Samuli Ripatti
Professor Samuli Ripatti has been appointed as Vice Director of the Institute for Molecular Medicine Finland (FIMM) for the period 1 May 2019 – 31 December 2022.
The Vice Director supports the FIMM Director in the development of FIMM as a whole, and in the absence or disqualification of the director acts as his or her deputy.
Samuli Ripatti is a Professor of Biometry at the Faculty of Medicine of the University of Helsinki and a Scholar at the Broad Institute of MIT and Harvard in Cambridge, MA, USA. Furthermore, he is the director of the Academy of Finland Centre of Excellence in Complex Disease Genetics. His research group studies genetic variation in the Finnish population and its effects on common complex disease risks and management. His research focuses in particular on cardiometabolic diseases as models to learn about disease mechanisms and genomic strategies for diagnoses and prevention. Samuli Ripatti has published over 250 articles that have been cited over 26,000 times. He is also currently chairing Doctoral Programmes in Biomedicine and Population Health.
To contact Samuli Ripatti, please e-mail or call to Sari Kivikko:
The FIMM Admin Team supports the Director of FIMM and the entire staff in daily activities as well as in the management and development of the Institute.
The FIMM SAB consists of seven internationally recognized experts in the institute's fields of research and technological activities.
SAB visits FIMM every two years. Based on the visit and documentation provided beforehand, the SAB prepares an evaluation report.
The previous evaluation reports are available through these links:
FIMM SAB until 2018
Chair: Professor Kai Simons, Max-Planck-Institute of Molecular Cell Biology and Genetics (DE)
Professor Cornelia van Duijn, Erasmus University Medical School (NL)
Professor Carl-Henrik Heldin, Ludwig Institute for Cancer Research, Uppsala University (SE)
Professor Edison Liu, The Jackson Laboratory (US)
Professor Nadia Rosenthal, The Jackson Laboratory (US)
The total yearly income of FIMM has steadily increased to the current, approximately 23 M€. In 2019, the basic funding from the University of Helsinki was around 3.1 M€. The vast majority of our funding thus arises from competitive external funding sources, mainly grants, external service income and industrial collaboration.
As compared to the University of Helsinki in general, FIMM receives a very high fraction of external funding from Business Finland, the EU and through industrial collaborations. During the last two years, our researchers have succeeded exceptionally well in establishing industrial collaborations and in receiving international public funding.
FIMM is committed to promoting equality and preventing discrimination in all its operations. We strive to promote trust and a positive and collegial atmosphere. We follow the University of Helsinki Equality Plan which features both HR policy and operative objectives for promoting various forms of equality at the University of Helsinki. Furthermore, we are participating in the Gender Equality working group of EU-LIFE - an alliance of leading research centres in life sciences.
In March 2006, the Ministry of Education commissioned the University of Helsinki to begin preparatory work to establish a research institute for molecular medicine as a joint undertaking with other biocentre universities as well as with other institutions in the field. The initiative of a group of experts nominated by the Academy of Finland and the Biotechnology 2005 committee report of the Ministry of Education formed the background for the assignment.
The University Senate decided to establish an international centre for molecular medicine on 20 September, 2006. The Senate approved its regulations on 13 December 2006. The regulations entered into effect on 1 April, 2007.
Besides the University of Helsinki, the Hospital District of Helsinki and Uusimaa (HUS) and the National Institute for Health and Welfare (THL; formerly National Public Health Institute, KTL) were involved in the establishment of the Institute. The Ministry of Education as well as The City of Helsinki, Orion Corporation, Jane and Aatos Erkko Foundation, Sigrid Jusélius Foundation, the Finnish Medical Foundation, and Orion-Farmos Research Foundation provided financial support for the Institute.
Annual reports and brochures:
Online annual reports:
Printed annual reports: